JP2015512612A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015512612A5 JP2015512612A5 JP2014552348A JP2014552348A JP2015512612A5 JP 2015512612 A5 JP2015512612 A5 JP 2015512612A5 JP 2014552348 A JP2014552348 A JP 2014552348A JP 2014552348 A JP2014552348 A JP 2014552348A JP 2015512612 A5 JP2015512612 A5 JP 2015512612A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- expression
- gene
- level
- biological sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 55
- 108090000623 proteins and genes Proteins 0.000 claims 37
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 31
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 31
- 239000005557 antagonist Substances 0.000 claims 31
- 239000012472 biological sample Substances 0.000 claims 28
- 239000000090 biomarker Substances 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 10
- 239000003795 chemical substances by application Substances 0.000 claims 7
- 238000002560 therapeutic procedure Methods 0.000 claims 7
- 239000002246 antineoplastic agent Substances 0.000 claims 6
- 239000000091 biomarker candidate Substances 0.000 claims 6
- 229960000397 bevacizumab Drugs 0.000 claims 5
- 229940127089 cytotoxic agent Drugs 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- -1 Col4a2 Proteins 0.000 claims 3
- 230000002491 angiogenic effect Effects 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 230000004043 responsiveness Effects 0.000 claims 3
- 101000659879 Homo sapiens Thrombospondin-1 Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 102100036034 Thrombospondin-1 Human genes 0.000 claims 2
- 239000002254 cytotoxic agent Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 108700026220 vif Genes Proteins 0.000 claims 2
- 102000004506 Blood Proteins Human genes 0.000 claims 1
- 108010017384 Blood Proteins Proteins 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 101150066399 COL4A1 gene Proteins 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 102100021811 E3 ubiquitin-protein ligase RNF5 Human genes 0.000 claims 1
- 102100021860 Endothelial cell-specific molecule 1 Human genes 0.000 claims 1
- 102100023721 Ephrin-B2 Human genes 0.000 claims 1
- 102100032031 Epidermal growth factor-like protein 7 Human genes 0.000 claims 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims 1
- 101000794587 Homo sapiens Cadherin-5 Proteins 0.000 claims 1
- 101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 claims 1
- 101001107084 Homo sapiens E3 ubiquitin-protein ligase RNF5 Proteins 0.000 claims 1
- 101000881679 Homo sapiens Endoglin Proteins 0.000 claims 1
- 101000897959 Homo sapiens Endothelial cell-specific molecule 1 Proteins 0.000 claims 1
- 101001049392 Homo sapiens Ephrin-B2 Proteins 0.000 claims 1
- 101000921195 Homo sapiens Epidermal growth factor-like protein 7 Proteins 0.000 claims 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims 1
- 101000972488 Homo sapiens Laminin subunit alpha-4 Proteins 0.000 claims 1
- 102100022743 Laminin subunit alpha-4 Human genes 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 101100490437 Mus musculus Acvrl1 gene Proteins 0.000 claims 1
- 108090000772 Neuropilin-1 Proteins 0.000 claims 1
- 108090000770 Neuropilin-2 Proteins 0.000 claims 1
- 101150034395 Nid2 gene Proteins 0.000 claims 1
- 102000001759 Notch1 Receptor Human genes 0.000 claims 1
- 108010029755 Notch1 Receptor Proteins 0.000 claims 1
- 102100023068 Protein kinase C-binding protein NELL1 Human genes 0.000 claims 1
- 102100034433 Protein kinase C-binding protein NELL2 Human genes 0.000 claims 1
- 238000011529 RT qPCR Methods 0.000 claims 1
- 102100037421 Regulator of G-protein signaling 5 Human genes 0.000 claims 1
- 101710140403 Regulator of G-protein signaling 5 Proteins 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 108700041286 delta Proteins 0.000 claims 1
- 101150109170 dll4 gene Proteins 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 239000013610 patient sample Substances 0.000 claims 1
- 239000000523 sample Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000007704 transition Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261586660P | 2012-01-13 | 2012-01-13 | |
| US61/586,660 | 2012-01-13 | ||
| PCT/US2013/021306 WO2013106765A1 (en) | 2012-01-13 | 2013-01-11 | Biological markers for identifying patients for treatment with vegf antagonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017237944A Division JP2018082705A (ja) | 2012-01-13 | 2017-12-12 | Ｖｅｇｆアンタゴニストで治療するための患者を同定するための生物学的マーカー |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015512612A JP2015512612A (ja) | 2015-04-30 |
| JP2015512612A5 true JP2015512612A5 (enExample) | 2016-03-03 |
| JP6529261B2 JP6529261B2 (ja) | 2019-06-12 |
Family
ID=48781962
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014552348A Expired - Fee Related JP6529261B2 (ja) | 2012-01-13 | 2013-01-11 | Ｖｅｇｆアンタゴニストで治療するための患者を同定するための生物学的マーカー |
| JP2017237944A Pending JP2018082705A (ja) | 2012-01-13 | 2017-12-12 | Ｖｅｇｆアンタゴニストで治療するための患者を同定するための生物学的マーカー |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017237944A Pending JP2018082705A (ja) | 2012-01-13 | 2017-12-12 | Ｖｅｇｆアンタゴニストで治療するための患者を同定するための生物学的マーカー |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20130216533A1 (enExample) |
| EP (1) | EP2802346B1 (enExample) |
| JP (2) | JP6529261B2 (enExample) |
| KR (1) | KR20140114415A (enExample) |
| CN (1) | CN104203268A (enExample) |
| AU (2) | AU2013207778B2 (enExample) |
| BR (1) | BR112014017320A2 (enExample) |
| CA (1) | CA2862835A1 (enExample) |
| HK (1) | HK1204933A1 (enExample) |
| IL (2) | IL233467B (enExample) |
| MX (1) | MX356802B (enExample) |
| NZ (1) | NZ627443A (enExample) |
| RU (1) | RU2659173C2 (enExample) |
| SG (1) | SG11201403927XA (enExample) |
| WO (1) | WO2013106765A1 (enExample) |
| ZA (1) | ZA201405305B (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112013031019A2 (pt) | 2011-06-02 | 2017-03-21 | Almac Diagnostics Ltd | teste diagnóstico molecular para câncer |
| US11091809B2 (en) | 2012-12-03 | 2021-08-17 | Almac Diagnostic Services Limited | Molecular diagnostic test for cancer |
| US10456470B2 (en) * | 2013-08-30 | 2019-10-29 | Genentech, Inc. | Diagnostic methods and compositions for treatment of glioblastoma |
| US10617755B2 (en) | 2013-08-30 | 2020-04-14 | Genentech, Inc. | Combination therapy for the treatment of glioblastoma |
| GB201409479D0 (en) * | 2014-05-28 | 2014-07-09 | Almac Diagnostics Ltd | Molecular diagnostic test for cancer |
| EP3117220B1 (en) * | 2014-03-12 | 2020-07-08 | Icahn School of Medicine at Mount Sinai | Method for identifying kidney allograft recipients at risk for chronic injury |
| EP3134119B1 (en) * | 2014-04-24 | 2018-08-22 | Pfizer Inc | Cancer treatment |
| GB201409476D0 (en) * | 2014-05-28 | 2014-07-09 | Almac Diagnostics Ltd | Molecular subtype for use in prognosis |
| GB201409478D0 (en) * | 2014-05-28 | 2014-07-09 | Almac Diagnostics Ltd | Pro-angiogenic signature |
| WO2015200887A2 (en) | 2014-06-26 | 2015-12-30 | Icahn School Of Medicine At Mount Sinai | Method for diagnosing subclinical and clinical acute rejection by analysis of predictive gene sets |
| EP3169801A1 (en) * | 2014-07-14 | 2017-05-24 | F. Hoffmann-La Roche AG | Diagnostic methods and compositions for treatment of glioblastoma |
| US10184154B2 (en) | 2014-09-26 | 2019-01-22 | Mayo Foundation For Medical Education And Research | Detecting cholangiocarcinoma |
| AU2015328411C1 (en) * | 2014-10-06 | 2022-03-03 | Dana-Farber Cancer Institute, Inc. | Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response |
| WO2016118670A1 (en) * | 2015-01-20 | 2016-07-28 | Memorial Sloan-Kettering Cancer Center | Multigene expression assay for patient stratification in resected colorectal liver metastases |
| EP3067698A1 (en) | 2015-03-11 | 2016-09-14 | Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Pd-ecgf as biomarker of cancer |
| CN107532124B (zh) | 2015-03-27 | 2022-08-09 | 精密科学公司 | 检测食管疾病 |
| EP3091084A1 (en) * | 2015-05-08 | 2016-11-09 | Université Catholique De Louvain | Methods for assessing the purity of a mesenchymal stem cells preparation |
| CN114712497B (zh) * | 2015-12-03 | 2024-03-22 | 雷杰纳荣制药公司 | 抗vegf剂在制备用于治疗新生血管性年龄相关性黄斑变性患者的药物中的用途 |
| US9845505B2 (en) | 2016-01-29 | 2017-12-19 | BluePrint Bio, Inc. | Prediction of therapeutic response in inflammatory conditions |
| MX2018012471A (es) * | 2016-04-15 | 2019-02-21 | Genentech Inc | Metodos de diagnostico y terapeuticos para el cancer. |
| CN109154027A (zh) * | 2016-04-15 | 2019-01-04 | 豪夫迈·罗氏有限公司 | 用于监测和治疗癌症的方法 |
| WO2018065434A1 (en) | 2016-10-07 | 2018-04-12 | Ventana Medical Systems, Inc. | Digital pathology system and associated workflow for providing visualized whole-slide image analysis |
| JP2018091846A (ja) * | 2016-12-01 | 2018-06-14 | 参天製薬株式会社 | 抗ｖｅｇｆ薬による滲出型加齢黄斑変性の処置の有効性を予測するための方法 |
| CN110546277B (zh) | 2017-03-01 | 2024-06-11 | 豪夫迈·罗氏有限公司 | 用于癌症的诊断和治疗方法 |
| US12070489B2 (en) | 2018-12-12 | 2024-08-27 | Rappaport Family Institute For Research In The Medical Sciences | Method of treating cancer with a cancer therapy in combination with another therapeutic agent |
| US12016900B2 (en) | 2017-06-04 | 2024-06-25 | Rappaport Family Institute For Research In The Medical Sciences | Method of treating cancer with an immune checkpoint inhibitor in combination with another therapeutic agent |
| EP3635410A4 (en) * | 2017-06-04 | 2021-03-10 | Rappaport Family Institute for Research in the Medical Sciences | PROCEDURE FOR PREDICTING PERSONALIZED RESPONSE TO CANCER TREATMENT USING IMMUNE CHECKPOINT INHIBITORS AND KITS |
| JP2018049015A (ja) * | 2017-09-26 | 2018-03-29 | マイクロ モーション インコーポレイテッド | 防炎性の電気フィードスルー |
| US11524053B2 (en) | 2018-01-26 | 2022-12-13 | The Regents Of The University Of California | Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents |
| CA3096222A1 (en) | 2018-04-06 | 2019-10-10 | Atyr Pharma, Inc. | Compositions and methods comprising anti-nrp2 antibodies |
| WO2019204267A1 (en) | 2018-04-16 | 2019-10-24 | Icahn School Of Medicine At Mount Sinai | Method and kits for prediction of acute rejection and renal allograft loss using pre-transplant transcriptomic signatures in recipient blood |
| US11519020B2 (en) | 2018-05-25 | 2022-12-06 | Regeneron Pharmaceuticals, Inc. | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF |
| WO2021034091A1 (ko) * | 2019-08-19 | 2021-02-25 | 재단법인 아산사회복지재단 | 교모세포종의 진단 방법 |
| CN114746120B (zh) | 2019-10-03 | 2024-07-30 | Atyr医药公司 | 包含抗nrp2抗体的组合物和方法 |
| IL293131A (en) | 2019-11-25 | 2022-07-01 | Univ California | Long-acting vegf inhibitors for intraocular neovascularization |
| US20240321393A1 (en) * | 2021-07-28 | 2024-09-26 | The Regents Of The University Of California | Cell-type optimization method and scanner |
| US11908560B2 (en) | 2021-08-11 | 2024-02-20 | OncoHost Ltd. | Cancer process evaluation |
| CN113834942B (zh) * | 2021-11-02 | 2024-02-02 | 河北特温特生物科技发展有限公司 | 一种胎盘生长因子质控品及其制备方法 |
| CN115840046A (zh) * | 2022-08-17 | 2023-03-24 | 中国药科大学 | 一种鉴别anti-VEGF抗体获得性耐药的蛋白聚糖ESM1生物学标记物及其应用 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4018653A (en) | 1971-10-29 | 1977-04-19 | U.S. Packaging Corporation | Instrument for the detection of Neisseria gonorrhoeae without culture |
| US4016043A (en) | 1975-09-04 | 1977-04-05 | Akzona Incorporated | Enzymatic immunological method for the determination of antigens and antibodies |
| US4424279A (en) | 1982-08-12 | 1984-01-03 | Quidel | Rapid plunger immunoassay method and apparatus |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5283187A (en) | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
| US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
| US5700637A (en) | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| AU4528493A (en) | 1992-06-04 | 1994-01-04 | Regents Of The University Of California, The | In vivo gene therapy with intron-free sequence of interest |
| US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
| US5910486A (en) | 1994-09-06 | 1999-06-08 | Uab Research Foundation | Methods for modulating protein function in cells using, intracellular antibody homologues |
| JP4312259B2 (ja) | 1995-04-27 | 2009-08-12 | アムジェン フレモント インク． | 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体 |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| DE69738539T2 (de) | 1996-12-03 | 2009-03-26 | Amgen Fremont Inc. | Vollkommen humane Antikörper die EGFR binden |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| ES2236634T3 (es) | 1997-04-07 | 2005-07-16 | Genentech, Inc. | Anticuerpos anti-vegf. |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| JP4460155B2 (ja) | 1997-12-05 | 2010-05-12 | ザ・スクリプス・リサーチ・インステイチユート | マウス抗体のヒト化 |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| DE69937291T2 (de) | 1998-04-02 | 2008-07-10 | Genentech, Inc., South San Francisco | Antikörpervarianten und fragmente davon |
| BR0008758A (pt) | 1999-01-15 | 2001-12-04 | Genentech Inc | Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| IL151865A0 (en) | 2000-03-31 | 2003-04-10 | Genentech Inc | Compositions and methods for detecting and quantifying gene expression |
| KR20030074693A (ko) | 2000-12-28 | 2003-09-19 | 알투스 바이올로직스 인코포레이티드 | 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법 |
| US7435419B2 (en) | 2002-07-19 | 2008-10-14 | Beth Israel Deaconess Medical Center | Methods of diagnosing and treating pre-eclampsia or eclampsia |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| WO2005044853A2 (en) | 2003-11-01 | 2005-05-19 | Genentech, Inc. | Anti-vegf antibodies |
| US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
| WO2005103281A2 (en) * | 2004-04-26 | 2005-11-03 | Children's Medical Center Corporation | Platelet biomarkers for the detection of disease |
| US20060008823A1 (en) | 2004-05-12 | 2006-01-12 | Kemp Jennifer T | DNA profiling and SNP detection utilizing microarrays |
| PL2069798T3 (pl) | 2006-10-04 | 2014-09-30 | Genentech Inc | Test ELISA dla VEGF |
| CA2675352A1 (en) | 2007-01-18 | 2008-07-24 | University Of Southern California | Genetic markers for predicting responsiveness to combination therapy |
| EP2065399A1 (en) | 2007-11-30 | 2009-06-03 | Siemens Healthcare Diagnostics GmbH | The present invention relates to methods for prediction of the therapeutic success of breast cancer therapy |
| JP2011502513A (ja) * | 2007-11-09 | 2011-01-27 | ジェネンテック， インコーポレイテッド | 癌患者における診断用途のための方法および組成物 |
| US20100029491A1 (en) * | 2008-07-11 | 2010-02-04 | Maike Schmidt | Methods and compositions for diagnostic use for tumor treatment |
| KR101596539B1 (ko) | 2008-12-23 | 2016-02-22 | 제넨테크, 인크. | 암 환자에서의 진단 목적용 방법 및 조성물 |
| KR101179843B1 (ko) | 2009-04-08 | 2012-09-04 | 경북대학교 산학협력단 | 뉴로필린 ２의 위암 진단 및 치료용 용도 |
| CA2766403A1 (en) | 2009-07-13 | 2011-01-20 | Genentech, Inc. | Diagnostic methods and compositions for treatment of cancer |
| KR20120059553A (ko) * | 2009-08-14 | 2012-06-08 | 제넨테크, 인크. | Ｖｅｇｆ 길항제에 대한 환자 반응을 모니터링하기 위한 생물학적 마커 |
| WO2011033006A1 (en) * | 2009-09-17 | 2011-03-24 | F. Hoffmann-La Roche Ag | Methods and compositions for diagnostics use in cancer patients |
| CA2787225A1 (en) * | 2010-01-12 | 2011-07-21 | Nestec S.A. | Methods for predicting response of triple-negative breast cancer to therapy |
| CN102711830A (zh) | 2010-01-19 | 2012-10-03 | 霍夫曼-拉罗奇有限公司 | 用于贝伐单抗联合疗法的基于肿瘤组织的生物标志 |
-
2013
- 2013-01-11 EP EP13736138.2A patent/EP2802346B1/en not_active Not-in-force
- 2013-01-11 SG SG11201403927XA patent/SG11201403927XA/en unknown
- 2013-01-11 WO PCT/US2013/021306 patent/WO2013106765A1/en not_active Ceased
- 2013-01-11 BR BR112014017320A patent/BR112014017320A2/pt not_active IP Right Cessation
- 2013-01-11 JP JP2014552348A patent/JP6529261B2/ja not_active Expired - Fee Related
- 2013-01-11 RU RU2014133164A patent/RU2659173C2/ru not_active IP Right Cessation
- 2013-01-11 KR KR1020147021823A patent/KR20140114415A/ko not_active Ceased
- 2013-01-11 CN CN201380013876.3A patent/CN104203268A/zh active Pending
- 2013-01-11 AU AU2013207778A patent/AU2013207778B2/en not_active Ceased
- 2013-01-11 NZ NZ627443A patent/NZ627443A/en not_active IP Right Cessation
- 2013-01-11 MX MX2014008463A patent/MX356802B/es active IP Right Grant
- 2013-01-11 CA CA2862835A patent/CA2862835A1/en not_active Abandoned
- 2013-01-11 HK HK15105537.2A patent/HK1204933A1/xx unknown
- 2013-03-15 US US13/837,343 patent/US20130216533A1/en not_active Abandoned
- 2013-03-15 US US13/836,535 patent/US10364466B2/en not_active Expired - Fee Related
-
2014
- 2014-06-30 IL IL233467A patent/IL233467B/en active IP Right Grant
- 2014-07-18 ZA ZA2014/05305A patent/ZA201405305B/en unknown
-
2017
- 2017-12-12 JP JP2017237944A patent/JP2018082705A/ja active Pending
-
2018
- 2018-01-12 AU AU2018200270A patent/AU2018200270A1/en not_active Abandoned
- 2018-01-24 IL IL257141A patent/IL257141A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015512612A5 (enExample) | ||
| RU2014133164A (ru) | Биологические маркеры для идентификации пациентов для лечения антагонистами vegf | |
| Wick et al. | Current status and future directions of anti-angiogenic therapy for gliomas | |
| Gordon‐Weeks et al. | Neutrophils promote hepatic metastasis growth through fibroblast growth factor 2–dependent angiogenesis in mice | |
| Liebner et al. | Thyroid cancer: pathogenesis and targeted therapy | |
| Torre et al. | New insights in lymphangioleiomyomatosis and pulmonary Langerhans cell histiocytosis | |
| JP2018508469A5 (enExample) | ||
| ES2931337T3 (es) | Un método para la identificación de combinaciones de inmunoterapia-fármacos usando un enfoque de red | |
| RU2017125053A (ru) | Терапевтические, диагностические и прогностические способы для рака мочевого пузыря | |
| RU2014143805A (ru) | Способы диагностики и композиции для лечения рака | |
| Charville et al. | Surgical pathology of gastrointestinal stromal tumors: practical implications of morphologic and molecular heterogeneity for precision medicine | |
| JP2012532628A5 (enExample) | ||
| RU2012109556A (ru) | Биологические маркеры для мониторирования ответа пациента на антагонисты vegf | |
| US20130252956A1 (en) | Methods of treating cancer | |
| JP2017523776A5 (enExample) | ||
| Li et al. | HIF-1α inhibitor YC-1 suppresses triple-negative breast cancer growth and angiogenesis by targeting PlGF/VEGFR1-induced macrophage polarization | |
| Kanda et al. | Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy | |
| Ordóñez-Morán et al. | Complex metastatic niches: already a target for therapy? | |
| Bagnasco et al. | Role of angiogenesis inhibitors in colorectal cancer: sensitive and insensitive tumors | |
| Cassinello et al. | Role of taxanes in advanced prostate cancer | |
| JP2015514062A5 (enExample) | ||
| Sheng et al. | Loss of breast cancer metastasis suppressor 1 promotes ovarian cancer cell metastasis by increasing chemokine receptor 4 expression | |
| Nisa et al. | Biological, diagnostic and therapeutic relevance of the MET receptor signaling in head and neck cancer | |
| Harshman et al. | First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma Database Consortium | |
| Rajhbeharrysingh et al. | Medical therapy for advanced forms of thyroid cancer |